Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myeloma Multiple: early-phase trial registry
3 of 8 indexed Myeloma Multiple trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Myeloma Multiple: 8 US clinical trials tracked, 3 recruiting.
Myeloma Multiple is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition myeloma-multiple
OPEN 3 | RECR 38% | LATE 0 | EARLY 7 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
Myeloma Multiple lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myeloma Multiple on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myeloma Multiple is recruiting below its size-band peers.
3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Myeloma Multiple research.
National Cancer Institute (NCI) accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Myeloma Multiple trials plan to enrol fewer than 100 people.
Median target enrolment is 79 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.
-
Myeloma Multiple research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics
NCT05651932
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
NCT05091372
Limited-duration Teclistamab
Abramson Cancer Center at Penn Medicine
NCT05932680
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
Alliance Foundation Trials
NCT04009109
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
NCT04782687
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
National Cancer Institute (NCI)
NCT03602612
Comprehensive Frailty Assessment
Ohio State University Comprehensive Cancer Center
NCT02033928
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
National Cancer Institute (NCI)
NCT03958656
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Myeloma Multiple records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myeloma Multiple trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myeloma Multiple page
8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Myeloma Multiple trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Myeloma Multiple trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myeloma Multiple condition card totals 8 registered trials; most-linked intervention Lenalidomide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.